Low-dose Tamoxifen Reduces Breast Cancer Risk in Women Diagnosed with Early Abnormal Breast Changes

A study shared at the 2018 San Antonio Breast Cancer Symposium showed the benefits of low-dose tamoxifen for reducing the risk of breast cancer developing in women diagnosed with early abnormal breast changes (not invasive breast cancer), including ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and atypical ductal hyperplasia (ADH). Breastcancer.org Chief Medical Officer Dr. Marisa Weiss explains what you should know about this research.